Designing antifilarial drug trials using clinical trial simulators

Martin Walker; Jonathan I. D. Hamley; Philip Milton; Frédéric Monnot; Belén Pedrique; Maria-Gloria Basáñez

doi:10.1038/s41467-020-16442-y

Nature Communications (Jun 2020)

Designing antifilarial drug trials using clinical trial simulators

Martin Walker,
Jonathan I. D. Hamley,
Philip Milton,
Frédéric Monnot,
Belén Pedrique,
Maria-Gloria Basáñez

Affiliations

Martin Walker: London Centre for Neglected Tropical Disease Research, Department of Pathobiology and Population Sciences, Royal Veterinary College, University of London
Jonathan I. D. Hamley: London Centre for Neglected Tropical Disease Research, Department of Infectious Disease Epidemiology, Imperial College London
Philip Milton: London Centre for Neglected Tropical Disease Research, Department of Infectious Disease Epidemiology, Imperial College London
Frédéric Monnot: Drugs for Neglected Diseases initiative, 15 Chemin Louis-Dunant 1202
Belén Pedrique: Drugs for Neglected Diseases initiative, 15 Chemin Louis-Dunant 1202
Maria-Gloria Basáñez: London Centre for Neglected Tropical Disease Research, Department of Infectious Disease Epidemiology, Imperial College London

DOI: https://doi.org/10.1038/s41467-020-16442-y
Journal volume & issue: Vol. 11, no. 1
pp. 1 – 11

Abstract

Read online

Drugs for filariases are under development and clinical trial simulators could help to inform the design of clinical trials. Here, Walker et al. use an individual-based onchocerciasis transmission model to project trial outcomes of a hypothetical macrofilaricidal drug, resolving key design choices.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal